Exelixis, Inc. (EXEL)
NASDAQ: EXEL · IEX Real-Time Price · USD
21.90
-0.22 (-0.99%)
At close: May 3, 2024, 4:00 PM
22.21
+0.31 (1.42%)
After-hours: May 3, 2024, 4:53 PM EDT
Exelixis Employees
Exelixis had 1,310 employees on December 31, 2023. The number of employees increased by 87 or 7.11% compared to the previous year.
Employees
1,310
Change (1Y)
87
Growth (1Y)
7.11%
Revenue / Employee
$1,409,653
Profits / Employee
$156,530
Market Cap
6.38B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Grifols | 23,737 |
Acadia Healthcare Company | 23,500 |
DENTSPLY SIRONA | 15,000 |
Elanco Animal Health | 9,800 |
Ionis Pharmaceuticals | 927 |
Blueprint Medicines | 655 |
ImmunityBio | 628 |
EXEL News
- 4 days ago - Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Business Wire
- 18 days ago - Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 - Business Wire
- 2 months ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March - Business Wire
- 2 months ago - Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments - GuruFocus
- 3 months ago - Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update - Business Wire
- 3 months ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February - Business Wire
- 3 months ago - Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 - Business Wire
- 3 months ago - Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 - Business Wire